Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

- PMLiVE

Merck & Co’s anacetrapib rescued by positive phase III trial

Data suggests drug reduces MACE compared to placebo

Digital disruption

How pharma is keeping up with the pace of change

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

Google’s Verily backs $300m European life sciences fund

The Medicxi fund for drug development firms also attracts support from Novartis

- PMLiVE

Trial of J&J’s canagliflozin boosts SGLT2 cardiovascular credentials

Invokana cuts risk of heart failure hospitalisation by a third

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Novartis tie-up with IBM Watson Health in breast cancer

Will combine real-world patient data and cognitive computing

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership

Lilly joins Personal Connected Health Alliance

Samsung, AT&T and IPSOS Healthcare also sign up

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

Europe needs ‘sustainable data ecosystem’

Better use of data must be made if patients and healthcare systems are to benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links